Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients

MLA

Daniele Calistri, et al. “Role of TP53 Mutations in Predicting Response to TKI Treatment in EGFR-Mutated NSCLC Patients.” Journal of Clinical Oncology, vol. 34, May 2016, p. 9052. EBSCOhost, https://doi.org/10.1200/jco.2016.34.15_suppl.9052.

APA

Daniele Calistri, Maximilian Papi, Marco Angelo Burgio, Alessandro Gamboni, Rita Chiari, Lucio Crinò, Laura Capelli, Claudia Casanova, Marita Mariotti, Chiara Bennati, Elisa Chiadini, Elisabetta Petracci, Nicoletta De Luigi, Paola Ulivi, Vienna Ludovini, Claudio Dazzi, Dino Amadori, Matteo Canale, & Angelo Delmonte. (2016). Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients. Journal of Clinical Oncology, 34, 9052. https://doi.org/10.1200/jco.2016.34.15_suppl.9052

Chicago

Daniele Calistri, Maximilian Papi, Marco Angelo Burgio, Alessandro Gamboni, Rita Chiari, Lucio Crinò, Laura Capelli, et al. 2016. “Role of TP53 Mutations in Predicting Response to TKI Treatment in EGFR-Mutated NSCLC Patients.” Journal of Clinical Oncology 34 (May): 9052. doi:10.1200/jco.2016.34.15_suppl.9052.